Prenatal exposure to methadone or buprenorphine alters µ‐opioid receptor binding and downstream signaling in the rat brain
Mette Kongstorp, Inger Lise Bogen, Synne Steinsland, Elisabeth Nerem, Triske Woshyar Salih, Tom Stiris, Jannike Mørch Andersen
Abstract
Abstract There is a growing concern related to the use of opioid maintenance treatment during pregnancy. Studies in both humans and animals have reported reduced cognitive functioning in offspring prenatally exposed to methadone or buprenorphine; however, little is known about the neurobiological mechanisms underlying these impairments. To reveal possible neurobiological effects of such in utero exposure, we examined brain tissue from methadone‐ and buprenorphine‐exposed rat offspring previously shown to display impaired learning and memory. We studied µ‐opioid receptor (MOR) and N‐methyl‐D‐aspartate receptor (NMDAR) binding in the rat offspring cerebrum during development and in the hippocampus at young adulthood. Moreover, we examined activation of the Ca 2+ /calmodulin‐dependent protein kinase II (CaMKII) and the extracellular signal‐regulated kinase (ERK), which are central in the downstream signaling of these receptors. The methadone‐ and buprenorphine‐exposed rat pups displayed reduced MOR binding up to two weeks after birth, whereas the NMDAR binding was unaffected. Prenatal exposure to methadone or buprenorphine also resulted in decreased activation of CaMKII and/or ERK during development, while young adult offspring displayed increased hippocampal ERK activation. In conclusion, our findings suggest that prenatal exposure to exogenous opioids, such as methadone or buprenorphine, may disturb the endogenous opioid system during development, with long‐term effects on proteins important for cognitive functioning.